Metagenomi, Inc. Common Stock (MGX)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on MGX

With Tiblio's Option Bot, you can configure your own wheel strategy including MGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MGX
  • Rev/Share 1.2227
  • Book/Share 5.7446
  • PB 0.3656
  • Debt/Equity 0.209
  • CurrentRatio 5.8455
  • ROIC -0.3111

 

  • MktCap 78501142.0
  • FreeCF/Share -2.8243
  • PFCF -0.7508
  • PE -0.9973
  • Debt/Assets 0.1492
  • DivYield 0
  • ROE -0.3205

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
MGX
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will host one-on-one investor meetings at the conference.

Read More
image for news Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

About Metagenomi, Inc. Common Stock (MGX)

  • IPO Date 2006-04-06
  • Website https://www.metagenomi.co
  • Industry Biotechnology
  • CEO Brian Charles Thomas
  • Employees 202
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.